Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health. (31st December 2022)

• Record Type: Journal Article
• Authors: Levit, Romina; Cortes-Perez, Naima G.; de Moreno de Leblanc, Alejandra; Loiseau, Jade; Aucouturier, Anne; Langella, Philippe; LeBlanc, Jean Guy; Bermúdez-Humarán, Luis G.
• Is Part Of: Gut microbes. Volume 14:Isuse 1(2022)
• Publication Date: 2022-12-31
• Subjects: Lactic acid bacteria -- lactococcus lactis -- lactobacillus spp -- bifidobacteria -- live delivery vectors -- mucosal vaccines; Gastrointestinal system -- Microbiology -- Periodicals; Microbiology -- Periodicals; Intestine, Small -- Periodicals; 616.3
• DOI: 10.1080/19490976.2022.2110821
• Languages: English
• ISSNs: 1949-0984

Abstract

ABSTRACT: There is now strong evidence to support the interest in using lactic acid bacteria (LAB)in particular, strains of lactococci and lactobacilli, as well as bifidobacteria, for the development of new live vectors for human and animal health purposes. LAB are Gram-positive bacteria that have been used for millennia in the production of fermented foods. In addition, numerous studies have shown that genetically modified LAB and bifodobacteria can induce a systemic and mucosal immune response against certain antigens when administered mucosally. They are therefore good candidates for the development of new mucosal delivery strategies and are attractive alternatives to vaccines based on attenuated pathogenic bacteria whose use presents health risks. This article reviews the most recent research and advances in the use of LAB and bifidobacteria as live delivery vectors for human and animal health.